Loss-of-function mutations in TRAF7 and KLF4 cooperatively activate RAS-like GTPase signaling and promote meningioma development
- Author
- P Najm, P Zhao, M Steklov, RN Sewduth, MF Baietti, S Pandolfi, N Criem, B Lechat, Teresa Maia (UGent) , Delphi Van Haver (UGent) , N Corthout, Sven Eyckerman (UGent) , Francis Impens (UGent) and AA Sablina
- Organization
- Abstract
- Meningiomas are the most common benign brain tumors. Mutations of the E3 ubiquitin ligase TRAF7 occur in 25% of meningiomas and commonly cooccur with mutations in KLF4, yet the functional link between TRAF7 and KLF4 mutations remains unclear. By generating an in vitro meningioma model derived from primary meningeal cells, we elucidated the cooperative interactions that promote meningioma development. By integrating TRAF7-driven ubiquitinome and proteome alterations in meningeal cells and the TRAF7 interactome, we identified TRAF7 as a proteostatic regulator of RAS-related small GTPases. Meningioma-associated TRAF7 mutations disrupted either its catalytic activity or its interaction with RAS GTPases. TRAF7 loss in meningeal cells altered actin dynamics and promoted anchorage-independent growth by inducing CDC42 and RAS signaling. TRAF deficiency-driven activation of the RAS/MAPK pathway promoted KLF4-dependent transcription that led to upregulation of the tumor-suppressive Semaphorin pathway, a negative regulator of small GTPases. KLF4 loss of function disrupted this negative feedback loop and enhanced mutant TRAF7-mediated cell transformation. Overall, this study provides new mechanistic insights into meningioma development, which could lead to novel treatment strategies. Significance: The intricate molecular cross-talk between the ubiquitin ligase TRAF7 and the transcription factor KLF4 provides a first step toward the identification of new therapies for patients with meningioma.
- Keywords
- GENOMIC ANALYSIS, TUMOR-SUPPRESSOR, CELLS, STABILITY, LZTR1, PROTEINS, MERLIN, GENE
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 1.77 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8722780
- MLA
- Najm, P., et al. “Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-like GTPase Signaling and Promote Meningioma Development.” CANCER RESEARCH, vol. 81, no. 16, 2021, pp. 4218–29, doi:10.1158/0008-5472.can-20-3669.
- APA
- Najm, P., Zhao, P., Steklov, M., Sewduth, R., Baietti, M., Pandolfi, S., … Sablina, A. (2021). Loss-of-function mutations in TRAF7 and KLF4 cooperatively activate RAS-like GTPase signaling and promote meningioma development. CANCER RESEARCH, 81(16), 4218–4229. https://doi.org/10.1158/0008-5472.can-20-3669
- Chicago author-date
- Najm, P, P Zhao, M Steklov, RN Sewduth, MF Baietti, S Pandolfi, N Criem, et al. 2021. “Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-like GTPase Signaling and Promote Meningioma Development.” CANCER RESEARCH 81 (16): 4218–29. https://doi.org/10.1158/0008-5472.can-20-3669.
- Chicago author-date (all authors)
- Najm, P, P Zhao, M Steklov, RN Sewduth, MF Baietti, S Pandolfi, N Criem, B Lechat, Teresa Maia, Delphi Van Haver, N Corthout, Sven Eyckerman, Francis Impens, and AA Sablina. 2021. “Loss-of-Function Mutations in TRAF7 and KLF4 Cooperatively Activate RAS-like GTPase Signaling and Promote Meningioma Development.” CANCER RESEARCH 81 (16): 4218–4229. doi:10.1158/0008-5472.can-20-3669.
- Vancouver
- 1.Najm P, Zhao P, Steklov M, Sewduth R, Baietti M, Pandolfi S, et al. Loss-of-function mutations in TRAF7 and KLF4 cooperatively activate RAS-like GTPase signaling and promote meningioma development. CANCER RESEARCH. 2021;81(16):4218–29.
- IEEE
- [1]P. Najm et al., “Loss-of-function mutations in TRAF7 and KLF4 cooperatively activate RAS-like GTPase signaling and promote meningioma development,” CANCER RESEARCH, vol. 81, no. 16, pp. 4218–4229, 2021.
@article{8722780, abstract = {{Meningiomas are the most common benign brain tumors. Mutations of the E3 ubiquitin ligase TRAF7 occur in 25% of meningiomas and commonly cooccur with mutations in KLF4, yet the functional link between TRAF7 and KLF4 mutations remains unclear. By generating an in vitro meningioma model derived from primary meningeal cells, we elucidated the cooperative interactions that promote meningioma development. By integrating TRAF7-driven ubiquitinome and proteome alterations in meningeal cells and the TRAF7 interactome, we identified TRAF7 as a proteostatic regulator of RAS-related small GTPases. Meningioma-associated TRAF7 mutations disrupted either its catalytic activity or its interaction with RAS GTPases. TRAF7 loss in meningeal cells altered actin dynamics and promoted anchorage-independent growth by inducing CDC42 and RAS signaling. TRAF deficiency-driven activation of the RAS/MAPK pathway promoted KLF4-dependent transcription that led to upregulation of the tumor-suppressive Semaphorin pathway, a negative regulator of small GTPases. KLF4 loss of function disrupted this negative feedback loop and enhanced mutant TRAF7-mediated cell transformation. Overall, this study provides new mechanistic insights into meningioma development, which could lead to novel treatment strategies. Significance: The intricate molecular cross-talk between the ubiquitin ligase TRAF7 and the transcription factor KLF4 provides a first step toward the identification of new therapies for patients with meningioma.}}, author = {{Najm, P and Zhao, P and Steklov, M and Sewduth, RN and Baietti, MF and Pandolfi, S and Criem, N and Lechat, B and Maia, Teresa and Van Haver, Delphi and Corthout, N and Eyckerman, Sven and Impens, Francis and Sablina, AA}}, issn = {{0008-5472}}, journal = {{CANCER RESEARCH}}, keywords = {{GENOMIC ANALYSIS,TUMOR-SUPPRESSOR,CELLS,STABILITY,LZTR1,PROTEINS,MERLIN,GENE}}, language = {{eng}}, number = {{16}}, pages = {{4218--4229}}, title = {{Loss-of-function mutations in TRAF7 and KLF4 cooperatively activate RAS-like GTPase signaling and promote meningioma development}}, url = {{http://doi.org/10.1158/0008-5472.can-20-3669}}, volume = {{81}}, year = {{2021}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: